정신분열증 환자에서 Sertraline의 병합투여가 혈장 Haloperidol 농도에 미치는 효과

The Effects of Sertraline on Plasma Haloperidol Concentrations in Schizophrenics

Objects Along with the increased interest in selective serotonin reuptake inhibitors recently, m any researches have undertaken to observe interactions with different drugs. In cases where schizophrenics with depressive or obsessive symptoms were shown and o f negative symptom schizophrenics, when selective serotonin reuptake inhibitor was administered together with antipsychotics, meaningful result was observed. Our research is to find out what would change to the concentration of plasm a haloperidol when sertraline is administered to patients who already are being treated with haloperidol. Method : Sixteen patients who are being treated with same dosage of haloperidol for at least 2weeks and did not respond to traditional antipsychotics, were administered with 50mg of sertraline for period of 2 weeks. Then, with the use of a H PLC equipped with UVdetector, the concentration changes between plasma haloperidol and the reduced haloperidol were observed. Result: The changes in the concentration o f haloperidol was from 8.52± 4.22ng/ml to 10.91 ± 5. 38ng/ml, so there was a significant increase(p<C0.01), however, the changes in the concentration of reduced haloperidol was from 7.41 ± 7.93ng/ml to 5.22± 6. lOng/ml, showing a significant decrease. And, the concentrations o plasma total haloperidol showed no significant changes at all. In com paring ratio of the reduced haloperidol and the haloperidol, the reduction ratio was down to 0.39±0.27 from 0.94±0.65 showing a significant decrease. Conclusion : There seems to be relatively low num ber of researches done on interaction were serotonergic drug is used with antipsychotics in spite of its clinically applicable possibility. According to similar researches done in the past, coadministering of such drugs not only increase the plasma concentration of antipsychotics but also, results in clinical improvement of negative symptoms and aggravation of extrapyramidal symptoms. The changes in clinical symptoms and adverse effects were not observed in our research, however, I think these observations need to be included as well in upcoming bigger scale studies.